Literature DB >> 28054302

microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.

Guang-Cheng Guo1, Jia-Xiang Wang2, Ming-Li Han1, Lian-Ping Zhang1, Lin Li1.   

Abstract

PURPOSE: Despite advances that have been made in systemic chemotherapy, the prognosis of advanced triple-negative breast cancer (TNBC) patients is still poor. The identification of key factors governing TNBC development is considered imperative for the development of novel effective therapeutic approaches. Previously, it has been reported that microRNA (miR)-761 may act as either a tumor suppressor or as an oncogene in different types of cancer. Here, we aimed at assessing the biological role of this miRNA in TNBC.
METHODS: First, we measured the expression of miR-761 in primary breast cancer tissues and breast cancer-derived cell lines using qRT-PCR. Subsequently, over-expression and silencing experiments were performed to determine the role of miR-761 in TNBC cell proliferation, colony formation, migration and invasion in vitro. The in vivo role of miR-761 in TNBC growth and metastasis was determined in mouse models. Bioinformatics analyses, dual-luciferase reporter assays, Western blot analyses and rescue experiments were performed to identify miR-761 target gene(s).
RESULTS: We found that miR-761 was up-regulated in primary breast cancer tissues and its derived cell lines and, particularly, in TNBC tissues and cell lines. We also found that exogenous miR-761 over-expression augmented in vitro TNBC cell proliferation, colony formation, migration and invasion, whereas miR-761 down-regulation impaired these features. In vivo, we found that miR-761 over-expression facilitated TNBC growth and lung metastasis. Mechanistically, miR-761 was found to negatively regulate the expression of tripartite motif-containing 29 (TRIM29) in TNBC cells by binding to the 3'-untranslated region of its mRNA. In conformity with these results, a significant negative correlation between miR-761 expression and TRIM29 protein expression was noted in primary TNBC tissues (r = -0.452, p = 0.0126). We also found that exogenous TRIM29 over-expression reversed the proliferative and invasive capacities of TNBC cells.
CONCLUSIONS: Our data indicate that miR-761 acts as an oncogene in TNBC. This mode of action can, at least partially, be ascribed to the down-regulation of its target TRIM29. We suggest that miR-761 may serve as a promising therapeutic target for TNBC.

Entities:  

Keywords:  Metastasis; TRIM29; Therapeutic target; Triple-negative breast cancer; miR-761

Mesh:

Substances:

Year:  2017        PMID: 28054302     DOI: 10.1007/s13402-016-0312-6

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  29 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells.

Authors:  Elisa Robles-Escajeda; Umashankar Das; Nora M Ortega; Karla Parra; Giulio Francia; Jonathan R Dimmock; Armando Varela-Ramirez; Renato J Aguilera
Journal:  Cell Oncol (Dordr)       Date:  2016-02-26       Impact factor: 6.730

Review 3.  MicroRNAs-mediated cell fate in triple negative breast cancers.

Authors:  Xinbing Sui; Xian Wang; Weidong Han; Da Li; Yinghua Xu; Fang Lou; Jichun Zhou; Xidong Gu; Jing Zhu; Cheng Zhang; Hongming Pan
Journal:  Cancer Lett       Date:  2015-03-03       Impact factor: 8.679

4.  TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.

Authors:  Jin Liu; Bryan Welm; Ken M Boucher; Mark T W Ebbert; Philip S Bernard
Journal:  Am J Pathol       Date:  2011-12-02       Impact factor: 4.307

5.  TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.

Authors:  Feng Qiu; Jian-Ping Xiong; Jun Deng; Xiao-Jun Xiang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers.

Authors:  Raihana Maqbool; Rabiya Rashid; Rehana Ismail; Saif Niaz; Nisar Ahmad Chowdri; Mahboob Ul Hussain
Journal:  Cell Oncol (Dordr)       Date:  2015-09-03       Impact factor: 6.730

7.  miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Tumour Biol       Date:  2015-11-12

8.  Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization.

Authors:  Lidong Wang; David G Heidt; Cheong J Lee; Huibin Yang; Craig D Logsdon; Lizhi Zhang; Eric R Fearon; Mats Ljungman; Diane M Simeone
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Methylation biomarkers for pleomorphic lobular breast cancer - a short report.

Authors:  Cathy B Moelans; Eva J Vlug; Cigdem Ercan; Peter Bult; Horst Buerger; Gabor Cserni; Paul J van Diest; Patrick W B Derksen
Journal:  Cell Oncol (Dordr)       Date:  2015-09-21       Impact factor: 6.730

Review 10.  Triple negative breast cancer: looking for the missing link between biology and treatments.

Authors:  Giuseppe Palma; Giuseppe Frasci; Andrea Chirico; Emanuela Esposito; Claudio Siani; Carmela Saturnino; Claudio Arra; Gennaro Ciliberto; Antonio Giordano; Massimiliano D'Aiuto
Journal:  Oncotarget       Date:  2015-09-29
View more
  22 in total

1.  LncRNA HOXA11-AS accumulation-induced microRNA-761 downregulation regulates cell growth by targeting TRIM29 in papillary thyroid cancer.

Authors:  Xiangdang Yin; Jian Zhang; Chaojun Li; Zhe Zhang; Tong Jin; Liyou Song; Rui Zhang; Wei Wang; Youmao Tao; Xiaochun Wang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

2.  Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species.

Authors:  Cathy E Richards; Sri H Vellanki; Yvonne E Smith; Ann M Hopkins
Journal:  Cell Oncol (Dordr)       Date:  2017-11-13       Impact factor: 6.730

3.  The abnormal expression of circ-ARAP2 promotes ESCC progression through regulating miR-761/FOXM1 axis-mediated stemness and the endothelial-mesenchymal transition.

Authors:  Pei Xu; Lei Wang; Qingtao Liu; Pengkai Gao; Fengqing Hu; Xiao Xie; Lianyong Jiang; Rui Bi; Fangbao Ding; Qi Yang; Haibo Xiao
Journal:  J Transl Med       Date:  2022-07-16       Impact factor: 8.440

4.  Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD).

Authors:  Prateek Sharma; Sanjeev Kumar
Journal:  Cell Oncol (Dordr)       Date:  2018-08-07       Impact factor: 6.730

5.  Functional Linkage of RKIP to the Epithelial to Mesenchymal Transition and Autophagy during the Development of Prostate Cancer.

Authors:  Mahmoud Ahmed; Trang Huyen Lai; Sahib Zada; Jin Seok Hwang; Trang Minh Pham; Miyong Yun; Deok Ryong Kim
Journal:  Cancers (Basel)       Date:  2018-08-16       Impact factor: 6.639

6.  Variation of Long Non-Coding RNA And mRNA Profiles in Breast Cancer Cells With Influences of Adipocytes.

Authors:  Xin-Hui Cao; Kai Yang; Ming-Xing Liang; Pei Ma; Di Xu; Yin-Jiao Fei; Wei Zhang; Xiu Chen; Jin-Hai Tang
Journal:  Front Oncol       Date:  2021-05-21       Impact factor: 6.244

7.  MicroRNA-761 promotes the sensitivity of colorectal cancer cells to 5-Fluorouracil through targeting FOXM1.

Authors:  Shuguang Cao; Limiao Lin; Xuanping Xia; Hao Wu
Journal:  Oncotarget       Date:  2017-08-10

8.  Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer.

Authors:  Xiaoyi Zhang; Xinyu Su; Zhe Guo; Xueqing Jiang; Xun Li
Journal:  J Clin Lab Anal       Date:  2020-03-18       Impact factor: 2.352

9.  Identification of FOXM1 as a specific marker for triple‑negative breast cancer.

Authors:  Yanli Tan; Qixue Wang; Yingbin Xie; Xiaoxia Qiao; Shun Zhang; Yanan Wang; Yongbin Yang; Bo Zhang
Journal:  Int J Oncol       Date:  2018-10-19       Impact factor: 5.650

10.  ATDC mediates a TP63-regulated basal cancer invasive program.

Authors:  Phillip L Palmbos; Yin Wang; Armand Bankhead Iii; Alan J Kelleher; Lidong Wang; Huibin Yang; McKenzie L Ahmet; Erica R Gumkowski; Samuel D Welling; Brian Magnuson; Jacob Leflein; Guadalupe Lorenzatti Hiles; Ethan V Abel; Michele L Dziubinski; Sumithra Urs; Mark L Day; Mats E Ljungman; Diane M Simeone
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.